Influx Healthtech Legal & Regulatory
NSE imposed a fine of Rs. 1.83 Lakhs on Influx Healthtech for a delay in submitting consolidated financial results for the half year ended March 31, 2026.
- Value
- ₹0.02 Cr
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
7 announcements with these filters
NSE imposed a fine of Rs. 1.83 Lakhs on Influx Healthtech for a delay in submitting consolidated financial results for the half year ended March 31, 2026.
Influx Healthtech Limited held its 6th Annual General Meeting on September 18, 2026. The company transacted the business items as per the AGM notice.
Influx Healthtech dispatched letters to shareholders without registered emails with the FY 2025-26 Annual Report weblink and 6th AGM notice. The letters are sent under Regulation 36(1)(b) of the SEBI Listing Regulations.
Influx Healthtech reported FY26 revenue of ₹146cr, a 41% YoY increase, with PAT at ₹20.5cr. Strategy focuses on scaling nutraceutical CDMO capacity by 2.5x through a new 75,000 sq ft facility.
Influx Healthtech delivered strong 41% YoY revenue growth in H2 FY26, driven by nutraceuticals, despite margin pressure from aggressive hiring ahead of massive capacity expansion.
Influx Healthtech delivered strong FY26 performance as a specialist CDMO in nutraceuticals and cosmetics, focusing on capacity expansion and new technology implementation following its 2025 NSE listing.
Influx Healthtech Ltd reported revenue from operations of ₹80.1 Cr (+41.0% YoY) and net profit of ₹10.5 Cr (+36.4% YoY) for H2 FY26.